Zobrazeno 1 - 9 of 9 pro vyhledávání: '"G. V. Forgeson"'
1
Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years’ experience in a national study in New Zealand
Autor: Michael H Bennett, D.J. Perez, B.M. Colls, P. I. Thompson, L. Skelton, C.M.A. Frampton, G. V. Forgeson, V. J. Harvey, I.C.S. Kennedy, P. J. Dady
Publikováno v: BJU International. 83:76-82
Objective To re-evaluate a national prospective study in New Zealand after 17 years to define whether orchidectomy alone and surveillance for nonseminoma germ cell testicular tumour (NSGCTT) is a sound policy and matches the results achieved by other
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::862fe5eb0598e253d1a135ee04db3567
https://doi.org/10.1046/j.1464-410x.1999.00869.x
Zobrazit plný text záznamu
2
Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer
Autor: Peter Dady, Paul Mitchell, P. Chapman, David Perez, G V Forgeson, Mark J. McKeage, B. D. Evans
Publikováno v: International Journal of Gynecologic Cancer. 4:66-71
Fifty-six patients with ovarian cancer (three stage IC, nine stage II, 33 stage III and II stage IV) were treated with carboplatin 350 mg m−2 i.v. day 1 and chlorambucil orally 0.15 mg kgm−1 days 1–7 inclusive, repeated every 28 days for eight
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8de4df71dd7f966e7ae8915aab6d72bf
https://doi.org/10.1046/j.1525-1438.1994.04010066.x
Zobrazit plný text záznamu
3
Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group
Autor: Peter Dady, B D Evans, G V Forgeson, Chris Atkinson, D Perez, Mark J. McKeage
Publikováno v: Journal of Clinical Oncology. 8:779-783
In a retrospective analysis, serial lung function tests from 81 patients receiving bleomycin were studied to determine the accuracy of carbon monoxide diffusing capacity (DLCO) as a predictor of clinically significant bleomycin lung. Six of 81 patien
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de06554bf6428e326926161137a99101
https://doi.org/10.1200/jco.1990.8.5.779
Zobrazit plný text záznamu
4
Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand
Autor: B M, Colls, V J, Harvey, L, Skelton, C M, Frampton, P I, Thompson, M, Bennett, D J, Perez, P J, Dady, G V, Forgeson, I C, Kennedy
Publikováno v: BJU international. 83(1)
To re-evaluate a national prospective study in New Zealand after 17 years to define whether orchidectomy alone and surveillance for nonseminoma germ cell testicular tumour (NSGCTT) is a sound policy and matches the results achieved by other treatment
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bdb726e503fc1f3aeb59dc0a35551065
https://pubmed.ncbi.nlm.nih.gov/10233456
Zobrazit plný text záznamu
5
Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres
Autor: J. Thomson, M. B. Jameson, D. H. Gray, S. G. Allan, V. J. Harvey, B. D. Evans, G. Humm, G. V. Forgeson, Paul Thompson
Publikováno v: Australian and New Zealand journal of medicine. 25(3)
Background : Adjuvant chemotherapy significantly improves survival of patients with non-metastatic osteosarcoma but most of the data come from trials conducted in major international cancer centres. Aim : To review the efficacy and toxicity of an adj
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86ee304046bf6a2c784b38efd4d27c7e
https://pubmed.ncbi.nlm.nih.gov/8744624
Zobrazit plný text záznamu
6
Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumours
Autor: L. Skelton, P. J. Dady, B. M. Colls, G. V. Forgeson, D.J. Perez, V. J. Harvey, P. I. Thompson
Publikováno v: British journal of urology. 70(4)
Summary— A series of 1 15 patients with clinical Stage I non-seminomatous germ cell testicular tumours were managed with orchiectomy and close surveillance (median follow-up 36 months, range 3-1 19); 34 (29.5%) relapsed, 21 within 6 months, 29 with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1183c26d4121d3957afd248e044202cb
https://pubmed.ncbi.nlm.nih.gov/1333336
Zobrazit plný text záznamu
7
Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics
Autor: P L, Mitchell, B D, Evans, S G, Allan, G V, Forgeson, D, Mak, L, Neave, G, Humm, G, Langley, D, Dickson, V J, Harvey
Publikováno v: The New Zealand medical journal. 105(929)
Ondansetron, a selective 5HT3 (serotonin) antagonist, was used in patients refractory to standard antiemetics. Seventy-five patients receiving chemotherapy without cisplatin were given ondansetron 4 mg IV and 4 mg orally immediately prior to chemothe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d3f344688a1817ced05846946d620de3
https://pubmed.ncbi.nlm.nih.gov/1532054
Zobrazit plný text záznamu
9
High dose melphalan with autologous marrow rescue in cancer treatment
Autor: J M, Dewar, G V, Forgeson, P J, Dady
Publikováno v: The New Zealand medical journal. 97(768)
Autologous bone marrow rescue circumvents the major toxicity of most cancer chemotherapeutic agents. Melphalan is a particularly well suited agent for use with autologous bone marrow rescue and produces response in chemo-resistant tumours. Thirteen p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bf6559202ba5cd82269e8e193ac1db6d
https://pubmed.ncbi.nlm.nih.gov/6390271
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje